Vera Therapeutics, Inc. · NASDAQ:VERA

Vera Therapeutics — Investor Presentation (June 2023)

27 slides from Vera Therapeutics's investor presentation, Jun 20, 2023

  1. Slide 1: Corporate Presentation June 2023

    Exhibit 99.1 Corporate Presentation June 2023 © 2023 VERA THERAPEUTICS, INC.

  2. Slide 2: Forward Looking Statements Disclaimer

    Forward Looking Statements Disclaimer This material has been made available to you with the consent of Vera Therapeutics, Inc. ( we , us , our , or the Company ). Statements in this presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statement

  3. Slide 3: Corporate Highlights

    Corporate Highlights • Lead clinical-stage asset, atacicept, targets B cells and plasma cells with pipeline-in-a-drug potential and well-characterized safety profile – Phase 2b program in IgA Nephropathy (IgAN): clinical data in hand support best-in-class potential, with positive data read-out in Ju

  4. Slide 4: Atacicept: Potential Value Creation Over Next Months

    Atacicept: Potential Value Creation Over Next 18 Months Catalyst 2023 2024 2025 2026 Initiated Phase 3 trial Q2 ✓ Presented 36-week data from ORIGIN trial Q2 ✓ 2H Present additional data from ORIGIN trial Q2, Q4 Present topline Phase 3 data 1H 2H BLA submission Projected launch Vera holds worldwide,

  5. Slide 5: Management Team: Successful Clinical and Commercial Track Record

    Management Team: Successful Clinical and Commercial Track Record Marshall Fordyce, MD Celia Lin, MD Sean Grant, MBA President and CEO Chief Medical Officer Chief Financial Officer • >15 years drug dev leadership • >10 years drug dev in Clinical • >15 years in corporate strategy, • 7 new drug approva

  6. Slide 6: Financial Position

    Financial Position ~$197M $25M Cash, cash equivalents, Credit facility available and marketable securities at Vera’s option (unaudited as of 3.31.23) Current capital position sufficient to fund IgAN-focused operations to ~44.3M Shares outstanding (as of 3.31.23) 2026 6 © 2023 VERA THERAPEUTICS, INC.

  7. Slide 7: Large Unmet Medical Need and Significant Commercial Opportunity

    Large Unmet Medical Need and Significant Commercial Opportunity ~$6–10B Annual Market Opportunity in 2 US, EU, and Japan for Novel IgAN Therapeutics Serious and progressive autoimmune disease of the kidney; average age of diagnosis 30 years IgAN Diagnosed Prevalence old, severely impacting quality o

  8. Slide 8: Rationale for Dual Inhibition of BLyS (BAFF) + APRIL with Atacicept for Patients with IgAN

    Rationale for Dual Inhibition of BLyS (BAFF) + APRIL with Atacicept for Patients with IgAN • Elevated BLyS plays key role in IgAN pathogenesis BLyS APRIL – BLyS and APRIL levels are both elevated in patients with IgAN and are 1-3 each associated with clinical severity – In preclinical models, overex

  9. Slide 9: Atacicept Binds BLyS and APRIL with Low Nanomolar Potency

    Atacicept Binds BLyS and APRIL with Low Nanomolar Potency BLyS APRIL Kd 1.45 nM Kd 0.672 nM 70 54 60 46 200 nM 50 38 100 nM 200 nM 50 nM 40 30 30 22 50 nM 20 14 10 nM 10 nM 10 2 nM 6 Buffer 0 -2 Buffer -10 -10 200 300 400 500 600 700 800 900 1000 200 280 360 440 520 600 680 760 840 920 1000 Time, s

  10. Slide 10: Atacicept Targets Upstream Hits of IgAN Pathogenesis

    Atacicept Targets Upstream Hits of IgAN Pathogenesis B Cell Maturation and Class-Switching Systemic Circulation Glomerulonephritis Lymphoid tissue BLyS IgA1 2 6 Plasma cell Plasma cell mistrafficking to the Gd-IgA1-containing APRIL systemic circulation immune complexes deposit in glomeruli 1 B cell

  11. Slide 11: Summary of Positive Phase 2b Week 36 Results

    Summary of Positive Phase 2b Week 36 Results PP Analysis ITT Analysis Met primary endpoint, with statistically significant *p<0.05 UPCR reductions on atacicept 150 mg Δ 43%*Δ 35%* Stable eGFR observed for patients on atacicept, Mean eGFR % change with atacicept 150 mg vs placebo was 11% (p=0.038), a

  12. Slide 12: ORIGIN Phase 2b IgAN Trial: Study Design and Objectives

    ORIGIN Phase 2b IgAN Trial: Study Design and Objectives Multinational, randomized, placebo-controlled trial Double-Blind Treatment Open-label Extension Placebo n=30 Atacicept 25 mg qwk n=15 Atacicept 150 mg qwk Atacicept 75 mg qwk n=30 Atacicept 150 mg qwk n=30 Week 0 24 36 96/ET 1° Endpoint 2° Endp

  13. Slide 13: 30% Placebo-Adjusted Reduction in Proteinuria Known to be Clinically Meaningful in IgAN

    30% Placebo-Adjusted Reduction in Proteinuria Known to be Clinically Meaningful in IgAN Patients • 30% placebo-adjusted reduction in proteinuria at week 36 is associated with 1 improvement of renal function in IgAN as measured by eGFR slope 2 • Placebo-adjusted reduction of 30% could delay ESRD by o

  14. Slide 14: Patient Disposition

    Patient Disposition Screened, n=232 Screen Failures, n=116 Randomized and Treated, n=116 All Atacicept, n=82 Placebo, n=34 n=82 Safety and ITT population n=34 Prespecified Week 36 PP analysis n=73 (89%) n=26 (76%) Excludes patients with protocol violations as identified by blinded third-party CRO Di

  15. Slide 15: Demographics and Baseline Characteristics

    Demographics and Baseline Characteristics Overall Atacicept 25 mg Atacicept 75 mg Atacicept 150 mg Placebo Mean ± SD or n (%) n=116 n=16 n=33 n=33 n=34 Age, y 39 40 41 38 39 Male sex 69 (59) 9 (56) 19 (58) 22 (67) 19 (56) Race White 62 (53) 7 (44) 12 (36) 17 (52) 26 (76) Asian 51 (44) 7 (44) 20 (61)

  16. Slide 16: UPCR % Change with Atacicept 150 mg at Week 36

    UPCR % Change with Atacicept 150 mg at Week 36 1 ITT Analysis PP Analysis 20 10 5% 3% 0 -10 -20 -30 Δ 35% -33% p=0.012 -40 Δ 43% -40% p=0.003 -50 Placebo Atacicept 150 mg Placebo Atacicept 150 mg n=26 n=26 n=34 n=33 p-values, percentage changes from baseline, and treatment differences were computed

  17. Slide 17: eGFR Change with Atacicept 150 mg Through Week 36

    eGFR Change with Atacicept 150 mg Through Week 36 15 10 5 1.6%Δ 11% p=0.038 0 5.8 2 mL/min/1.73 m -5 Absolute difference in mean change at week 36 -10 -8.5% -15 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 Week n= Placebo 34 34 34 34 34 30 Atacicept 150 mg 33 33 33 32 32 31 ITT analysis; p-va

  18. Slide 18: Dose-dependent Reductions Observed in Serum IgG, IgA, and IgM Through Week 36

    Dose-dependent Reductions Observed in Serum IgG, IgA, and IgM Through Week 36 IgG IgA IgM 0 0 0 0% -3% -4% * * * * -14% * -20 * -20 -20 * * * * * * * * -32% -32% * -37% -40 -40 -40 * * * * * * * * * * -54% * * * -59% -60 -60 -60 -63% * * * * -70% * -73% * * -80 -80 -80 0 4 8 12 16 20 24 28 32 36 0 4

  19. Slide 19: Gd-IgA1 % Change Through Week 36

    Gd-IgA1 % Change Through Week 36 20 0 -7% * -20 * * * * -40 -39% * * * * -62% -60 * -64% * * -80 0 4 8 12 16 20 24 28 32 36 Week n= Placebo 33 33 33 33 29 Atacicept 25 mg 16 16 16 15 15 Atacicept 75 mg 33 33 33 33 33 Atacicept 150 mg 32 32 30 30 30 ITT analysis; *p<0.001 vs placebo. p-values, percen

  20. Slide 20: Treatment-Emergent Adverse Events Through Week 36

    Treatment-Emergent Adverse Events Through Week 36 Atacicept 25 mg Atacicept 75 mg Atacicept 150 mg Placebo Patients, n (%) n=16 n=33 n=33 n=34 TEAEs 11 (69) 24 (73) 25 (76) 27 (79) 1 Study drug-related TEAEs 6 (38) 17 (52) 19 (58) 14 (41) 2 3 4 Serious TEAEs 0 1 (3) 1 (3) 3 (9) TEAEs leading to stud

  21. Slide 21: Summary of Clinical Safety Data Through Week 36

    Summary of Clinical Safety Data Through Week 36 Atacicept was generally well tolerated in IgAN patients, with no reported deaths, low rate (2%) of serious AEs overall, and 1 patient (1%) discontinued atacicept due to AE Infections were balanced between atacicept and placebo No study drug-related ser

  22. Slide 22: Atacicept for IgAN Regulatory Update

    Atacicept for IgAN Regulatory FDA Type C meeting Q4’22 & written feedback received Q2’23 enabled Update alignment on Ph3 protocol to accelerate Ph3 trial start in early June Ability to leverage ORIGIN worldwide sites Rapidly Advance Investigator familiarity with Ph2 dosing administration Phase 3 Mul

  23. Slide 23: ORIGIN Subgroup Analyses Informed Phase 3 Design to Maximize Competitive Positioning

    ORIGIN Subgroup Analyses Informed Phase 3 Design to Maximize Competitive Positioning • Tested atacicept’s anticipated commercial formulation and setting (at home SC self administration) in patients with wide-spectrum disease severity and racially diverse backgrounds • Incorporated evolving SOC SGLT2

  24. Slide 24: Initiated Phase 3 Pivotal Trial in June 2023

    Initiated Phase 3 Pivotal Trial in June 2023 Atacicept Once Weekly SC Injection Formulation in Phase 3, Same as Phase 2b Double-Blind Treatment Open-label Extension Placebo Atacicept 150 mg qwk Atacicept 150 mg qwk Week 0 36 104 156 1° Endpoint 2° Endpoint UPCR: n=200 eGFR: n=376 Inclusion Criteria

  25. Slide 25: Attractive Commercial Drug Product Profile

    Attractive Commercial Drug Product Profile • Self-administration of small volume (1 mL) via autoinjector at commercial launch • Smallest volume among B-cell modifying drugs in development (2–4 mL with APRIL-only) • Large subcutaneous injection volumes are associated with pain and may affect tolerabi

  26. Slide 26: Atacicept: Potential Value Creation Over Next Months

    Atacicept: Potential Value Creation Over Next 18 Months Catalyst 2023 2024 2025 2026 Initiated Phase 3 trial Q2 ✓ Presented 36-week data from ORIGIN trial Q2 ✓ 2H Q2, Q4 Present ongoing data from ORIGIN 2 trial Present topline Phase 3 data 1H 2H BLA submission Projected launch Vera holds worldwide,

  27. Slide 27: © 2023 VERA THERAPEUTICS, INC.

    © 2023 VERA THERAPEUTICS, INC.

Vera Therapeutics — Investor Presentation (June 2023) on 6ix